Last reviewed · How we verify
Other atypical antipsychotic drugs
Other atypical antipsychotic drugs is a Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. It is currently FDA-approved.
At a glance
| Generic name | Other atypical antipsychotic drugs |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Caplyta in Borderline Personality Disorder (PHASE2)
- Effect of SC-ICBT for Adults With OCD：A Three-Arm Randomized Controlled Trial (NA)
- National Pregnancy Registry for Psychiatric Medications
- Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI) (PHASE3)
- An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia (PHASE3)
- VA Aripiprazole vs Esketamine for Treatment Resistant Depression (PHASE4)
- Brexpiprazole in Borderline Personality Disorder (PHASE2)
- Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other atypical antipsychotic drugs CI brief — competitive landscape report
- Other atypical antipsychotic drugs updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI
Frequently asked questions about Other atypical antipsychotic drugs
What is Other atypical antipsychotic drugs?
Other atypical antipsychotic drugs is a Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
Who makes Other atypical antipsychotic drugs?
Other atypical antipsychotic drugs is developed and marketed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (see full Johnson & Johnson Pharmaceutical Research & Development, L.L.C. pipeline at /company/johnson-johnson-pharmaceutical-research-development-l-l-c).
What development phase is Other atypical antipsychotic drugs in?
Other atypical antipsychotic drugs is FDA-approved (marketed).